newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

  • Ascentage Pharma Group International announced that Chairman & CEO Dr. Dajun Yang will host investor webcasts on December 11, 2025, to update stakeholders on the company's portfolio & pipeline ahead of the 67th ASH Annual Meeting.
  • An English language webcast with Q&A is scheduled for 8:30 am EST / 9:30 pm HKT on December 11, 2025, with a replay available on the company website.
  • A Chinese language webcast with Q&A will be held at 9:00 pm EST / 10:00 am HKT on December 12, 2025.
  • The company is a global, commercial-stage biopharmaceutical firm focused on cancer therapies, including inhibitors targeting Bcl-2, MDM2-p53, & next-generation kinase inhibitors.
  • Olverembatinib is the first approved product, a third-generation BCR-ABL1 inhibitor for CML patients with T315I mutations or resistance to prior TKIs, covered by China's NRDL.
  • Global registrational Phase III trials for Olverembatinib include the FDA-cleared POLARIS-2 study for CML, plus trials for newly diagnosed Ph+ ALL & SDH-deficient GIST.
  • Lisaftoclax is the second approved product, a Bcl-2 inhibitor for CLL/SLL patients previously treated with BTK inhibitors, commercialized in China following NMPA approval.
  • Four global registrational Phase III trials for Lisaftoclax are ongoing: GLORA (combination with BTK inhibitors for refractory CLL/SLL), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (newly diagnosed AML), & GLORA-4 (newly diagnosed HR MDS).
  • The GLORA-4 study received simultaneous clearance from the US FDA, EU EMA, & China CDE.
  • Ascentage Pharma holds global IP rights & maintains partnerships with companies such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent, alongside collaborations with institutions like Dana-Farber & Mayo Clinic.
  • The press release includes standard forward-looking statements regarding future events, operations, & financial conditions subject to risks & uncertainties.